ARTES receives French Research Tax Credit (CIR) Accreditation

ARTES Biotech­nol­o­gy GmbH today announced that it has just obtained gov­ern­men­tal approval for ‘Crédit d’Im­pôt Recherche’ (CIR) for a three-year peri­od from the French Min­istry of High­er Edu­ca­tion and Research (MESR).

The French R&D tax cred­it CIR gives French com­pa­nies the abil­i­ty to claim tax relief on 30% on all gen­er­at­ed costs out­sourced to ARTES’ R&D services.
“We are pleased to receive this accred­i­ta­tion and to be approved as valid and reli­able R&D provider from the French Min­istry”, Dr Michael Pio­ntek, Man­ag­ing Direc­tor of ARTES. “It allows our cus­tomers in France to ben­e­fit from tax relief of their R&D expens­es com­mit­ted to us and it will help us to tie up our rela­tion­ships with our present clients in France and to install new collaborations”.

ARTES Biotech­nol­o­gy is glob­al­ly active as R&D com­pa­ny spe­cial­ized in devel­op­ing bio­phar­ma­ceu­ti­cal and vac­cine pro­duc­tion processes.
The com­pa­ny oper­ates world­wide from its 850 m² S1 facil­i­ties in Lan­gen­feld, from where it also offers cell line engi­neer­ing based on yeast (Hansenu­la poly­mor­pha) and bac­te­r­i­al (E. coli and Bacil­lus) expres­sion plat­forms, lab scale up- and down­stream process devel­op­ment, sup­ply of non-GMP bulk mate­r­i­al (API) for activ­i­ty and tox­i­c­i­ty tests and tech­nol­o­gy trans­fer to cGMP facil­i­ties and scale-up support.